RT Book, Section
A1 Smith, Stephen D.
A1 Press, Oliver W.
A2 Press, Oliver W.
A2 Lichtman, Marshall A.
A2 Leonard, John P.
SR Print(0)
ID 1148368604
T1 Diffuse Large B-Cell Lymphoma and Related Neoplasms
T2 Williams Hematology Malignant Lymphoid Diseases
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781260117066
LK hemonc.mhmedical.com/content.aspx?aid=1148368604
RD 2024/04/19
AB SUMMARYDiffuse  large  B-cell  lymphomas  (DLBCLs)  comprise  a  heterogeneous  group  of  aggressive  malignancies  of  large,  transformed  B  lymphocytes.  DLBCL  is  the  most  common  lymphoma  in  the  world  and  accounts  for  approximately  25  to  30  percent  of  lymphoma  cases  in  the  United  States.  The  incidence  increases  with  age,  with  a  median  age  at  presentation  in  the  sixth  decade.  The  disease  typically  presents  as  a  rapidly  growing  mass  that  may  involve  either  lymph  node  or  extranodal  sites  and  often  is  associated  with  systemic  symptoms.  Approximately  50  to  60  percent  of  patients  will  present  with  advanced-stage,  disseminated  disease.  DLBCL  is  curable  with  combination  chemotherapy.  For  localized  disease,  either  three  cycles  of  rituximab,  cyclophosphamide,  doxorubicin,  vincristine,  and  prednisone  (R-CHOP)  plus  involved-field  radiation  therapy  or  six  cycles  of  (R-CHOP)  are  recommended,  whereas  for  advanced-stage  DLBCL,  six  cycles  of  R-CHOP  are  appropriate.  High-dose  chemotherapy  with  autologous  stem  cell  transplantation  may  be  curative  for  patients  with  DLBCL  that  relapses  after  treatment  with  frontline  chemotherapy.